In:
Journal of Bone and Mineral Research, Wiley, Vol. 14, No. S2 ( 1999-11), p. 21-28
Abstract:
The molecular mechanisms underlying Paget's disease and subsequent osteosarcoma formation are not well understood. In this study, we aim to delineate the function of the c‐Fos oncogene in Paget's disease using transgenic mice, based on previous findings that c‐Fos is highly expressed in Pagetic osteoclasts and that c‐Fos is an essential gene for osteoclast differentiation and skeletal neoplasia. We have generated transgenic mice in which c‐Fos is overexpressed specifically in osteoclasts using the tartrate‐resistant acid phosphatase (TRAP) promoter, and five founder mice have been identified. All transgene‐expressing animals developed severe bone remodeling lesions, some of which progressed to large bone tumors. Histopathologic analysis indicated that the lesions contained a marked increase in the number of osteoclasts that contained a large number of nuclei. Osteoclasts were identified by histochemical staining for TRAP and by in situ hybridization for matrix metalloproteinase‐9 (MMP‐9) expression. Moreover, transgenic osteoclasts, and in some cases, osteoblasts and chondrocytes, expressed high levels of c‐Fos protein as judged by immunocytochemistry. This phenotype of increased osteoclast number and activity, together with an apparently high rate of bone turnover, resembles some characteristics of Paget's disease. These data therefore support an important function for c‐Fos in the Pagetic phenotype, and further support the notion that this gene is important in osteoclastogenesis and in bone remodeling disorders.
Type of Medium:
Online Resource
ISSN:
0884-0431
,
1523-4681
DOI:
10.1002/jbmr.5650140206
Language:
English
Publisher:
Wiley
Publication Date:
1999
detail.hit.zdb_id:
2008867-X
